Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Franciosi, Lui G ; Diamant, Zuzana LU ; Banner, Katharine H ; Zuiker, Rob ; Morelli, Nicoletta ; Kamerling, Ingrid M C ; de Kam, Marieke L ; Burggraaf, Jacobus ; Cohen, Adam F and Cazzola, Mario , et al. (2013) In The Lancet Respiratory Medicine 1(9). p.714-727
Abstract
Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but those with severe disease often respond poorly to these classes of drug. We assessed the efficacy and safety of a novel inhaled dual phosphodiesterase 3 (PDE3) and PDE4 inhibitor, RPL554 for its ability to act as a bronchodilator and anti-inflammatory drug.
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Lancet Respiratory Medicine
volume
1
issue
9
pages
714 - 727
publisher
Elsevier
external identifiers
  • pmid:24429275
  • wos:000342691000020
  • scopus:84887115924
ISSN
2213-2600
DOI
10.1016/S2213-2600(13)70187-5
language
English
LU publication?
yes
id
33b40e8f-608d-4097-84a8-36f3bd11be2c (old id 4291379)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24429275?dopt=Abstract
date added to LUP
2016-04-01 14:07:22
date last changed
2022-03-29 19:12:47
@article{33b40e8f-608d-4097-84a8-36f3bd11be2c,
  abstract     = {{Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but those with severe disease often respond poorly to these classes of drug. We assessed the efficacy and safety of a novel inhaled dual phosphodiesterase 3 (PDE3) and PDE4 inhibitor, RPL554 for its ability to act as a bronchodilator and anti-inflammatory drug.}},
  author       = {{Franciosi, Lui G and Diamant, Zuzana and Banner, Katharine H and Zuiker, Rob and Morelli, Nicoletta and Kamerling, Ingrid M C and de Kam, Marieke L and Burggraaf, Jacobus and Cohen, Adam F and Cazzola, Mario and Calzetta, Luigino and Singh, Dave and Spina, Domenico and Walker, Michael J A and Page, Clive P}},
  issn         = {{2213-2600}},
  language     = {{eng}},
  number       = {{9}},
  pages        = {{714--727}},
  publisher    = {{Elsevier}},
  series       = {{The Lancet Respiratory Medicine}},
  title        = {{Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.}},
  url          = {{http://dx.doi.org/10.1016/S2213-2600(13)70187-5}},
  doi          = {{10.1016/S2213-2600(13)70187-5}},
  volume       = {{1}},
  year         = {{2013}},
}